Purpose: To investigate the expression of inflammatory markers HLA-DR in impression cytology specimens from patients receiving topical antiglaucoma monotherapy. Methods: Impression cytology specimens were obtained from patients taking no topical medication (n = 13) and from primary open-angle glaucoma or ocular hypertensive patients taking one topical medication for at least 3 months (latanoprost n = 14; betaxolol n = 12; timolol n = 14). None of the patients had any signs of ocular surface inflammation as detected by slit-lamp examination, a normal Schirmer’s test and tear breakup time. The expression of HLA-DR on epithelial cells and T lymphocytes was analysed by flow cytometry. Results: A significant increase in HLA-DR on epithelial cells in patients on monotherapy was detected (latanoprost p < 0.05; betaxolol p < 0.01; timolol p < 0.01). Although the duration of treatment differed significantly between individual groups, there was no significant correlation between the length of monotherapy and the expression of inflammatory markers by epithelial cells and T lymphocytes. In the latanoprost group, the increased expression of HLA-DR was associated with a shorter duration of treatment. Conclusions: The flow-cytometric results indicate that administration of a single topical medication preserved with benzalkonium chloride, irrespective of type, for 3 months or more induced a significant degree of subclinical inflammation detected as increased expression of HLA-DR on conjunctival epithelial cells.

1.
Sherwood MB, Grierson I, Millar L, Hitchings RA: Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology 1989;96:327–335.
2.
Broadway DC, Grierson I, O’Brien C, Hitchings RA: Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994;112:1437–1445.
3.
Broadway DC, Grierson I, O’Brien C, Hitchings RA: Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 1994;112:1446–1454.
4.
Lavin MJ, Wormald RP, Migdal CS, Hitchings RA: The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990;108:1543–1548.
5.
Turacli E, Budak K, Kaur A, Mizrak B, Ekinci C: The effects of long-term topical glaucoma medication on conjunctival impression cytology. Int Ophthalmol 1997;21:27–33.
6.
Brandt JD, Wittpenn JR, Katz LJ, Steinmann WN, Spaeth GL: Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol 1991;112:297–301.
7.
Wright P: Squamous metaplasia or epidermalization of the conjunctiva as an adverse reaction to topical medication. Trans Ophthalmol Soc UK 1979;99:244–246.
8.
Herreras JM, Pastor JC, Calonge M, Asensio VM: Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992;99:1082–1088.
9.
Steuhl KP, Knorr M, Frohn A, Thiel HJ: Effect of antiglaucoma eyedrops on cell differentiation of the conjunctiva. Fortschr Ophthalmol 1991;88:865–869.
10.
Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P: Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 1994;101:454–460.
11.
Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M, et al: Ocular surface inflammatory changes induced by topical antiglaucoma drugs: Human and animal studies. Ophthalmology 1999;106:556–563.
12.
Harrison SA, Mondino BJ, Kagan JM: Modulation of HLA antigen expression on conjunctival fibroblasts by gamma interferon. Invest Ophthalmol Vis Sci 1990;31:163–167.
13.
Borish L, Rosenwasser LJ: Continuing medical education: Update on cytokines. J Allergy Clin Immunol 1996;97:719–734.
14.
Hanafusa T, Pujol-Borrell R, Chiavoto L, Russell TCG, Doniach D, Botazzo GF: Aberrant expression of HLA-DR antigens on thyrocytes of Graves’ disease: Relevance for autoimmunity. Lancet 1983;ii:1111–1114.
15.
Hall BM, Bishop GA, Duggin GG, Horvath JS, Philips J, Tiller DJ: Increased expression of HLA-DR antigens on renal tubular cells in renal transplants: Relevance to the rejection response. Lancet 1984;ii:247–251.
16.
Baudouin C, Haouat N, Brignole F, Brignole J, Gastaud P: Immunopathological findings in conjunctival cells using immunofluorescence staining of impression cytology specimens. Br J Ophthalmol 1992;76:545–549.
17.
Zierhut M, Thiel HJ, Weidle EG, Daal JG, Müller C: Abnormale Expression von HLA-Klasse-II-Antigenen auf Bindehautepithelien bei peripheren Hornhaut-Ulzera. Klin Monatsbl Augenheilkd 1987;191:174–178.
18.
Mabey DC, Bailey RL, Dunn D, Jones D, Williams JH, Whittle HC, Ward ME: Expression of MHC class II antigens by conjunctival epithelial cells in trachoma: Implications concerning the pathogenesis of blinding disease. J Clin Pathol 1991;44:285–289.
19.
Baudouin C, Brignole F, Becquet F, Pisella PJ, Goguel A: Flow cytometry in impression cytology specimens: A new method for evaluation of conjunctival inflammation. Invest Ophthalmol Vis Sci 1997;38:1458–1464.
20.
Fujihara T, Takeuchi T, Saito K, Tsubota K: Flow cytometric analysis of surface antigens on human conjunctival cells. Ophthalmic Res 1997;29:103–109.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.